Eslam Maher @eslammaher.bsky.social · 16/05/2026A chance to listen to J. Jack Lee comment on FDA's guidance on Bayesian statistics in trials www.linkedin.com/feed/update/... Here's his letter, alongside co-authors Harrell & Spiegelhalter et al in JAMA: jamanetwork.com/journals/jam... 010
Eslam Maher @eslammaher.bsky.social · 11/05/2026Pharma-Stat meeting in Basket Trial Designs in early-phase oncology. The presenters will discuss a computationally-cheap approach (power prior) for borrowing. Date & Time: Saturday, May 16, 2026. 10:00am-12:00pm, EST. www.linkedin.com/posts/yuanye... 010
Eslam Maher @eslammaher.bsky.social · 22/04/2026Boston University Seminar: Improving Decision-Making in Oncology Basket Clinical Trials: Challenges of Small Sample Sizes and Heterogeneous Treatment Effects Presented by Haolin Li 12 May 2026 Zoom Meeting ID: 998 0913 5732 Passcode: 201194 www.linkedin.com/posts/leohao... 000
Eslam Maher @eslammaher.bsky.social · 17/04/2026FDA novel oncology drug approvals in 2025 Table includes requirement for randomised dose finding and post-marketing dose optimization www.parexel.com/insights/blo... 000
Eslam Maher @eslammaher.bsky.social · 03/03/2026No, not at all. I re-checked Agresti and Coull (1998), and they seem to "strongly" favor Wilson's but were looking for a simpler formula, like Wald's, to be presented in classrooms, but with better coverage. www.tandfonline.com/doi/abs/10.1... 1/2 210
Eslam Maher @eslammaher.bsky.social · 02/11/2025This seed produces 30 successes in a row! 🤯 h/t Andi Fugard @andifugard.info www.linkedin.com/posts/andifu... #rstats 181
Eslam Maher @eslammaher.bsky.social · 30/10/2025Hierarchy of causal inference for treatment efficacy via @f2harrell.bsky.social 020